Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23688606 | 0.85 | CYP2C19 (0.65) | CYP2C19KMT2AMEN1SMN1; SMN2TSHR | |
| SCHEMBL8669701 | 0.85 | CYP2C19 (0.65) | CYP2C19KMT2AMEN1SMN1; SMN2TSHR | |
| SCHEMBL23688603 | 0.85 | CYP2C19 (0.65) | CYP2C19KMT2AMEN1SMN1; SMN2TSHR | |
| SCHEMBL20274587 | 0.85 | KMT2A (0.59) | CYP2C19KMT2AESR1ESR2MEN1 | |
| SCHEMBL3168058 | 0.85 | KMT2A (0.59) | CYP2C19KMT2AESR1ESR2MEN1 | |
| SCHEMBL17731413 | 0.84 | KMT2A (0.50) | CYP2C19KMT2AESR1ESR2MEN1 | |
| SCHEMBL6848701 | 0.84 | LTA4H (0.52) | CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL14445158 | 0.82 | CYP2C19 (0.45) | CYP2C19KMT2AMEN1ALDH1A1 | |
| SCHEMBL8720943 | 0.82 | ALDH1A1 (0.46) | CYP2C19KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14445142 | 0.82 | CPN1 (0.51) | CYP2C19KMT2AESR1ESR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-4332135-A1 | METHOD FOR PREPARING POLYMER, AND OBTAINED POLYMER | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11242319-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242319-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2019-03-28 | — | — | US | disclosed |
| EP-3215141-A2 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073738-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073738-A2 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-1995011880-A1 | SUBSTITUTED AMIDES AS TACHYKININ ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242319-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | CYP2C19 3094/4885KMT2A 1557/4885ESR1 3892/4885 |
| US-20190092729-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | CYP2C19 3094/4885KMT2A 1557/4885ESR1 3892/4885 |
| US-11932601-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | CYP2C19 3094/4885KMT2A 1557/4885ESR1 3892/4885 |
| US-20220274926-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | CYP2C19 3094/4885KMT2A 1557/4885ESR1 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.